AIM ImmunoTech Inc. financial data

Symbol
AIM on NYSE
Industry
Biological Products, (No Diagnostic Substances)
Location
2117 Sw Highway 484, Ocala, Florida
State of incorporation
Florida
Fiscal year end
December 31
Former names
HEMISPHERX BIOPHARMA INC (to 8/26/2019)
Latest financial report
Q1 2024 - May 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 297 % -85.9%
Return On Equity -184 % -293%
Return On Assets -128 % -191%
Operating Margin -17.3K % -28.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 49.9M shares +3.09%
Common Stock, Shares, Outstanding 50.3M shares +3.81%
Entity Public Float 31.8M USD -12.2%
Common Stock, Value, Issued 50K USD +4.17%
Weighted Average Number of Shares Outstanding, Basic 49.5M shares +2.19%
Weighted Average Number of Shares Outstanding, Diluted 49.5M shares +2.19%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 193K USD +22.9%
Revenue from Contract with Customer, Excluding Assessed Tax 193K USD +22.9%
Research and Development Expense 10.8M USD +35.4%
General and Administrative Expense 22.7M USD +70.5%
Costs and Expenses 33.5M USD +58.1%
Operating Income (Loss) -33.4M USD -58.3%
Net Income (Loss) Attributable to Parent -31.1M USD -61.4%
Earnings Per Share, Basic -0.64 USD/shares -60%
Earnings Per Share, Diluted -0.64 USD/shares -50%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.3M USD -85.9%
Marketable Securities, Current 7.65M USD +2.59%
Accounts Receivable, after Allowance for Credit Loss, Current 1.18M USD -29.4%
Assets, Current 11.3M USD -65.9%
Property, Plant and Equipment, Net 118K USD -23.9%
Operating Lease, Right-of-Use Asset 763K USD -3.66%
Other Assets, Noncurrent 1.69M USD +15.9%
Assets 16.2M USD -56.8%
Accounts Payable, Current 6.57M USD +582%
Employee-related Liabilities, Current 451K USD +2553%
Accrued Liabilities, Current 1.45M USD +108%
Liabilities, Current 9.88M USD +438%
Operating Lease, Liability, Noncurrent 537K USD -15.6%
Liabilities 11.4M USD
Retained Earnings (Accumulated Deficit) -415M USD -8.1%
Stockholders' Equity Attributable to Parent 4.83M USD -86.2%
Liabilities and Equity 16.2M USD -56.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.82M USD -30.8%
Net Cash Provided by (Used in) Financing Activities 2.83M USD +2729%
Net Cash Provided by (Used in) Investing Activities -158K USD -103%
Common Stock, Shares Authorized 350M shares 0%
Common Stock, Shares, Issued 50.3M shares +3.81%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.14M USD +41.4%
Deferred Tax Assets, Valuation Allowance 36.8M USD +19.4%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 38.4M USD +20.2%
Operating Lease, Liability 777K USD -4.66%
Depreciation 9K USD -18.2%
Payments to Acquire Property, Plant, and Equipment 86K USD +110%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -31.1M USD -61.4%
Property, Plant and Equipment, Gross 1.45M USD
Operating Lease, Liability, Current 240K USD +34.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 244K USD +13%
Lessee, Operating Lease, Liability, to be Paid, Year One 273K USD +12.8%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 128K USD -28.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 159K USD -20.5%
Deferred Tax Assets, Operating Loss Carryforwards 25.1M USD +27.7%
Preferred Stock, Shares Authorized 5M shares
Lessee, Operating Lease, Liability, to be Paid, Year Four 133K USD -33.5%
Additional Paid in Capital 419M USD +0.23%
Amortization of Intangible Assets 49K USD +36.1%
Interest Expense 72K USD
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares